Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

Ab­b­Vie will end the last parts of its CD47 agree­ment with I-Mab, the Mary­land and Shang­hai biotech dis­closed in a Fri­day SEC fil­ing.

The Chica­go-area drug­mak­er will re­turn the glob­al rights to de­vel­op and com­mer­cial­ize cer­tain CD47 an­ti­bod­ies and prod­ucts that were set up un­der the orig­i­nal 2020 and amend­ed 2022 tie-ups, I-Mab said.

Last Au­gust, Ab­b­Vie opt­ed out of part of their pact. But I-Mab could still have gained as much as $1.295 bil­lion in pay­outs based on where the deal stood at that time. The de­ci­sion to en­tire­ly end the agree­ment was “based on the pre­vi­ous pro­gram dis­con­tin­u­a­tion and Ab­b­Vie’s strate­gic de­ci­sion,” I-Mab said in the fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER